PLoS ONE (May 2010)

Toxicology and drug delivery by cucurbit[n]uril type molecular containers.

  • Gaya Hettiarachchi,
  • Duc Nguyen,
  • Jing Wu,
  • Derick Lucas,
  • Da Ma,
  • Lyle Isaacs,
  • Volker Briken

DOI
https://doi.org/10.1371/journal.pone.0010514
Journal volume & issue
Vol. 5, no. 5
p. e10514

Abstract

Read online

BackgroundMany drug delivery systems are based on the ability of certain macrocyclic compounds - such as cyclodextrins (CDs) - to act as molecular containers for pharmaceutical agents in water. Indeed beta-CD and its derivatives have been widely used in the formulation of hydrophobic pharmaceuticals despite their poor abilities to act as a molecular container (e.g., weak binding (K(a)10(4) M(-1)) and therefore show great promise as a drug delivery system.MethodologyIn this study we investigated the toxicology, uptake, and bioactivity of two cucurbit[n]urils (CB[5] and CB[7]) and three CB[n]-type containers (Pentamer 1, methyl hexamer 2, and phenyl hexamer 3). All five containers demonstrated high cell tolerance at concentrations of up to 1 mM in cell lines originating from kidney, liver or blood tissue using assays for metabolic activity and cytotoxicity. Furthermore, the CB[7] molecular container was efficiently internalized by macrophages indicating their potential for the intracellular delivery of drugs. Bioactivity assays showed that the first-line tuberculosis drug, ethambutol, was as efficient in treating mycobacteria infected macrophages when loaded into CB[7] as when given in the unbound form. This result suggests that CB[7]-bound drug molecules can be released from the container to find their intracellular target.ConclusionOur study reveals very low toxicity of five members of the cucurbit[n]uril family of nanocontainers. It demonstrates the uptake of containers by cells and intracellular release of container-loaded drugs. These results provide initial proof-of-concept towards the use of CB[n] molecular containers as an advanced drug delivery system.